UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical translation of nuclear export inhibitors in cancer

Seminars in cancer biology, 2014-08, Vol.27, p.74-86

2014

Volltextzugriff (PDF)

Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain

Molecular biology of the cell, 2011-05, Vol.22 (10), p.1791-1805

2011

Volltextzugriff (PDF)

PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1836-1845

2021

Volltextzugriff (PDF)

A Structurally Tunable DNA-Based Extracellular Matrix

Journal of the American Chemical Society, 2010-10, Vol.132 (42), p.14727-14729

2010

Volltextzugriff (PDF)

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.683-683

2021

Volltextzugriff (PDF)

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Blood, 2019-11, Vol.134 (Supplement_1), p.2997-2997

2019

Volltextzugriff (PDF)

Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.LB-308-LB-308

2017

Volltextzugriff (PDF)

Abstract 5404: PAK4 allosteric modulators (PAMs) repress the Wnt/β-catenin signaling pathway and tumor growth

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5404-5404

2015

Volltextzugriff (PDF)

Abstract A24: Novel small molecule PAK4 allosteric modulators show potency against oncogenic K-Ras driven pancreatic cancer

Molecular cancer research, 2014-12, Vol.12 (12_Supplement), p.A24-A24

2014

Volltextzugriff (PDF)

Abstract PR1: In silico designed covalent peptidomimetic inhibitors (KPT-SINE) of CRM1 modulate tumor suppressor protein nuclear export and induce apoptosis in cancer cells

Cancer research (Chicago, Ill.), 2012-07, Vol.72 (13_Supplement), p.PR1-PR1

2012

Volltextzugriff (PDF)

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth

Molecular cancer therapeutics, 2016-09, Vol.15 (9), p.2119-2129

2016

Volltextzugriff (PDF)

Nucleo-cytoplasmic transport as a therapeutic target of cancer

Journal of hematology and oncology, 2014-12, Vol.7 (1), p.85-85, Article 85

2014

Volltextzugriff (PDF)

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Nature communications, 2018-02, Vol.9 (1), p.502-14, Article 502

2018

Volltextzugriff (PDF)

Therapeutic Potential of Targeting PAK Signaling

Anti-cancer agents in medicinal chemistry, 2016-01, Vol.16 (1), p.75-88

2016

Volltextzugriff (PDF)

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2018-05, Vol.18 (5), p.335-345

2018

Volltextzugriff (PDF)

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth

Scientific reports, 2017-02, Vol.7 (1), p.42555-42555, Article 42555

2017

Volltextzugriff (PDF)

Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4116-4116

2023

Volltextzugriff (PDF)

Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models

Nature communications, 2024-09, Vol.15 (1), p.7875-17

2024

Volltextzugriff (PDF)

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

Clinical cancer research, 2017-05, Vol.23 (10), p.2528-2541

2017

Volltextzugriff (PDF)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer

International journal of molecular sciences, 2019-09, Vol.20 (19), p.4826

2019

Volltextzugriff (PDF)

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

Gut, 2017-08, Vol.66 (8), p.1358-1368

2017

Volltextzugriff (PDF)

CBMT-22. REVERSING THE WARBURG EFFECT BY TARGETING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT), THE RATE-LIMITING ENZYME OF NAD+ SALVAGE PATHWAY INCREASES, CHEMOSENSITIVITY TO TEMOZOLOMIDE IN GLIOMA CELLS

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi37-vi38

2019

Volltextzugriff (PDF)

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Nature (London), 2016-10, Vol.538 (7623), p.114-117

2016

Volltextzugriff (PDF)

A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS627-TPS627

2023

Volltextzugriff (PDF)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Oncotarget, 2016-11, Vol.7 (48), p.78883-78895

2016

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Englisch
(129)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Humans
(35)
Life Sciences & Biomedicine
(33)
Animals
(22)
Cell Line, Tumor
(21)
Oncology
(19)
Mice
(18)
Antineoplastic Agents - Pharmacology
(14)
Apoptosis - Drug Effects
(14)
Xenograft Model Antitumor Assays
(14)
Exportin 1 Protein
(13)
Apoptosis
(12)
Cell Proliferation - Drug Effects
(12)
Acrylamides - Pharmacology
(10)
Cancer
(10)
Female
(10)
Karyopherins - Metabolism
(10)
Receptors, Cytoplasmic And Nuclear - Metabolism
(10)
Active Transport, Cell Nucleus - Drug Effects
(9)
Aminopyridines - Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical translation of nuclear export inhibitors in cancer

Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain

PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus

A Structurally Tunable DNA-Based Extracellular Matrix

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma

Abstract 5404: PAK4 allosteric modulators (PAMs) repress the Wnt/β-catenin signaling pathway and tumor growth

Abstract A24: Novel small molecule PAK4 allosteric modulators show potency against oncogenic K-Ras driven pancreatic cancer

Abstract PR1: In silico designed covalent peptidomimetic inhibitors (KPT-SINE) of CRM1 modulate tumor suppressor protein nuclear export and induce apoptosis in cancer cells

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth

Nucleo-cytoplasmic transport as a therapeutic target of cancer

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Therapeutic Potential of Targeting PAK Signaling

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth

Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses

Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

CBMT-22. REVERSING THE WARBURG EFFECT BY TARGETING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT), THE RATE-LIMITING ENZYME OF NAD+ SALVAGE PATHWAY INCREASES, CHEMOSENSITIVITY TO TEMOZOLOMIDE IN GLIOMA CELLS

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Suchergebnisse filtern